BioAge Labs (BIOA) stock

Market cap $324M

$6.81
-3.95%

Market closed. Prices as of Thursday's close.

Quality Score
-5
Poor
In its industry
#232of 276
Next2H 2026“…measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026”Trial data · 8-K, Aug 5

Follow BIOA's trial news. Pro members can get an alert when BioAge Labs files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when BIOA files news on its trialsFree for 24 hours. No account needed.
Pipeline and cash

What's next for BIOA, and how long its cash lasts

From BioAge Labs’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“…dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026”Trial data · 8-K, Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
BGE-102
Another trial
QUELL-CVPhase 2 · Active · 160 people · main data estimated Nov 30, 2026 · NCT07656727

1 more trial, 3 more milestones and 16 filings, for Pro members.

Cash runway

The company says its cash lasts through 2029 (8-K, Aug 5).

That is the company's own estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 24, 2026)
  • At-the-market share sales program (S-3ASR, filed Mar 24, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Shane Barton, sold 62,566 shares on Jun 30, under a planned sale. 6 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade, and Kristen Fortney’s 10 filings and quotes.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why it's down

Down 71% in 3 months, 36% under its 50-day average.

Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.

−2Long-term trend below a falling 200-day average, down over two years

4 more things pulling BIOA's score down, for Pro members

What's next

Expected to report Thu Nov 5, after the close

After its last 4 reports it closed -3.2% on average, higher 2 of 4 times.

What would turn BIOA's score around: 8 things, for Pro members

Alert me when BIOA's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest
A card on the scanner, shown on AMD
A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart
A stock page
The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist
The scanner
The 14 checks

Nothing is firing on BIOA right now

One per group is shown here.

Trend1 of 5 shown

Averages stacked in order, price near its high.

Volume1 of 3 shown

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

The daily range is tight against its own recent history.

Buying1 of 3 shown

Closes near the high, and buyers step in on dips.

The other 10 checks on BIOA, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1426.4

    Below 30.

  • MACD (12, 26, 9)Above signal

    Crossed above its signal line 27 sessions ago.

  • The price is 37.3% below it.

  • The price is 59.3% below it. The 50-day is below the 200-day, since Sep 3.

  • ADX 1443.9

    25 or more, with +DI below -DI.

  • Support$6.75

    Swing low from Nov 7, 2025, 0.9% below the price.

  • Swing high from Sep 22, 25.3% above the price.

  • The bands run from $6.43 to $9.80.

  • Volume0.9x

    Against its 20-day average, for the time of day.

Its industry

How BIOA ranks in Biotech

BIOA is #232 of 276 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

Earnings

When does BIOA report earnings, and what happens after?

Expected to report Thu Nov 5, after the close (in 34 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 5, 2026After close-0.7%+2.6%-4.5%
May 8, 2026Before open-1.7%+0.9%+5.0%
Mar 24, 2026Before open-0.8%-13.5%-15.0%
Nov 6, 2025After close-2.7%-2.8%+3.4%

The gap is the next open against the close before the report; the reaction is where that session closed. BIOA closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About BioAge Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

62 employeesEmeryville, CAbioagelabs.com

Pro

Every line of the score, on every stock.

  • Real-time prices, no delay
  • Every line of BIOA's score, with the points and the reason
  • All 14 checks on BIOA and on all 2,958 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on BIOA
See all 14 checks on BIOAFree for 24 hours. No account needed. Then keep going with a free account.
Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.